Market Place
Sourcing Support
Byondis nomme Louis Denis, M.D., au poste de Chief Medical Officer
19 Nov 2024 //
BUSINESSWIRE
U.S. FDA Issues Complete Response Letter for Byondis` Trastuzumab Duocarmazine
16 May 2023 //
PR NEWSWIRE
Byondis Initiates PI Study of Next Generation Antibody-Drug Conjugate BYON3521
25 Aug 2022 //
PRNEWSWIRE
EMA Validates MAA for Trastuzumab Duocarmazine (SYD985) in HER2-Positive MBC
18 Jul 2022 //
PRNEWSWIRE
FDA Accepts Byondis` BLA for [Vic-] Trastuzumab Duocarmazine (SYD985)
12 Jul 2022 //
PRNEWSWIRE
Byondis and Medac link up to commercialise trastuzumab duocarmazine
03 May 2022 //
PHARMATIMES
Byondis Partners with Medac to Commercialize Antibody-Drug Conjugate
03 May 2022 //
CONTRACTPHARMA
Byondis ESMO Presentation Confirms ADC Trastuzumab Duocarmazine is Superior
19 Sep 2021 //
PRNEWSWIRE
Byondis to Share Results of Pivotal Phase III Metastatic Breast Cancer Trial
16 Sep 2021 //
FIRSTWORDPHARMA
Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&D
15 Jul 2021 //
PR NEWSWIRE
Phase III breast cancer trial meets primary endpoint
10 Jun 2021 //
PHARMAFILE
Byondis` trastuzumab ADC hits main goal of Phase III breast cancer study
08 Jun 2021 //
B3CNEWSWIRE
Byondis ready to link up to bring Herceptin-booster to market after phase 3 win
08 Jun 2021 //
FIERCEBIOTECH
Byondis Initiates Ph I trials of ADC as treatment of HER2-Expressing Tumors
24 Aug 2020 //
BIOSPECTRUMASIA
Byondis Initiates Ph I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib
24 Aug 2020 //
PRESS RELEASE
Byondis initiates phase I study of antibody-drug conjugate SYD1875
11 Aug 2020 //
SELECTSCIENCE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.